These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 1244959)

  • 1. Letter: Oral dihydroergotamine in management of cluster headache.
    Herzberg L; Lenman JA
    Br Med J; 1976 Jan; 1(6001):96. PubMed ID: 1244959
    [No Abstract]   [Full Text] [Related]  

  • 2. Is orally inhaled dihydroergotamine (DHE) equivalent in efficacy in migraine to intravenous DHE?
    Tfelt-Hansen P
    Headache; 2014 Feb; 54(2):383. PubMed ID: 24512579
    [No Abstract]   [Full Text] [Related]  

  • 3. Dihydroergotamine: role in the treatment of migraine.
    Schürks M
    Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1141-8. PubMed ID: 19624283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous dihydroergotamine for inpatient management of refractory primary headaches.
    Nagy AJ; Gandhi S; Bhola R; Goadsby PJ
    Neurology; 2011 Nov; 77(20):1827-32. PubMed ID: 22049203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Iatrogenic ergotism].
    Zicot M
    Rev Med Liege; 1977 Jan; 32(2):43-7. PubMed ID: 841212
    [No Abstract]   [Full Text] [Related]  

  • 6. [Calcium carbasalate-metoclopramide combination versus dihydroergotamine in the treatment of migraine attacks].
    Pradalier A; Guérard des Lauriers A; Scheck F; Peraudeau P; Lacoste JP; Cajfinger F
    Pathol Biol (Paris); 1995 Nov; 43(9):806-13. PubMed ID: 8746103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosing and administration of ergotamine tartrate and dihydroergotamine.
    Mathew NT
    Headache; 1997; 37 Suppl 1():S26-32. PubMed ID: 9009471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus. Working Panel of the Headache and Facial Pain Section of the American Academy of Neurology.
    Silberstein SD; Young WB
    Neurology; 1995 Mar; 45(3 Pt 1):577-84. PubMed ID: 7898722
    [No Abstract]   [Full Text] [Related]  

  • 9. Effectiveness of subcutaneous dihydroergotamine by home injection for migraine.
    Becker WJ; Riess CM; Hoag J
    Headache; 1996 Mar; 36(3):144-8. PubMed ID: 8984085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ergot pharmacology and alternative delivery systems for ergotamine derivatives.
    Goldstein J
    Neurology; 1992 Mar; 42(3 Suppl 2):45-6. PubMed ID: 1557192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IV dihydroergotamine therapy for migraine treatment.
    Stein M
    Ann Emerg Med; 1988 Jul; 17(7):764. PubMed ID: 3382085
    [No Abstract]   [Full Text] [Related]  

  • 12. [Letter: Treatment of idiopathic cyclic edema syndromes. Value of dihydroergotoamine methanesulfonate].
    Ader JL; Durnad D; Lopez B; Suc JM
    Nouv Presse Med; 1975 May; 4(20):1506. PubMed ID: 1215153
    [No Abstract]   [Full Text] [Related]  

  • 13. Oral methylergonovine maleate for refractory migraine and cluster headache prevention.
    Saper JR; Evans RW
    Headache; 2013 Feb; 53(2):378-81. PubMed ID: 23432443
    [No Abstract]   [Full Text] [Related]  

  • 14. Dihydroergotamine nasal spray.
    Gijsman HJ; Ferrari MD
    Neurology; 1995 Feb; 45(2):397-8. PubMed ID: 7854552
    [No Abstract]   [Full Text] [Related]  

  • 15. Repetitive intravenous dihydroergotamine as therapy for intractable migraine.
    Raskin NH
    Neurology; 1986 Jul; 36(7):995-7. PubMed ID: 3520384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dihydroergotamine suppositories in a headache clinic.
    Ward TN; Scott G
    Headache; 1991 Jul; 31(7):465-6. PubMed ID: 1774163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Observations of the "carry-over effect" following successful termination of chronic migraine in the adolescent with short-term dihydroergotamine, dexamethasone and hydroxyzine: a pilot study.
    Charles JA; Jotkowitz S
    J Headache Pain; 2005 Feb; 6(1):51-4. PubMed ID: 16362192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of morning migraine. Clinical and biokinetic correlation of programmed-release dihydroergotamine].
    Aylward M; Chazot G; Maddock J; Schott B
    Presse Med; 1984 Jun; 13(26):1617-9. PubMed ID: 6234558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, safety, and tolerability of dihydroergotamine nasal spray as monotherapy in the treatment of acute migraine. Dihydroergotamine Nasal Spray Multicenter Investigators.
    Headache; 1995 Apr; 35(4):177-84. PubMed ID: 7775172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comment: Outcomes of migraine therapy with IV dihydroergotamine.
    Charles A
    Neurology; 2016 Mar; 86(9):859. PubMed ID: 26843565
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.